Department of Spine Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Orthopedics, The Fifth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
J Bone Miner Res. 2015 Aug;30(8):1523-35. doi: 10.1002/jbmr.2481. Epub 2015 May 26.
LIM mineralization protein-1 (LMP-1) is an intracellular regulator of bone formation. Upregulation of bone morphogenetic proteins (BMPs) and stabilization of BMP/Smad signaling have been proven to be the key mechanisms through which LMP-1 enhances osteogenesis. However, how LMP-1 regulates BMPs expression and related bone formation remains unclear. In this study, a LMP-1-induced osteogenesis cell model was used to study the molecular action of LMP-1 on BMP-2 expression and bone formation. The results show that overexpression of LMP-1 significantly increases, whereas downregulation of endogenous LMP-1 decreases BMP-2 expression and bone formation. Antagonism of BMP-2 with noggin or short hairpin BMP-2 significantly attenuates the osteoinductive effect of LMP-1, suggesting that the osteoinductive effect of LMP-1 is mediated by BMP-2. LMP-1 regulation of BMP-2 is found to occur at the transcription level using a luciferase reporter assay with a reporter construct containing a BMP-2 promoter. A promoter deletion assay reveals that -1000/-500 bp is the key regulated region by LMP-1. A Runx2-binding site is then located at -934/-920 bp and confirmed by luciferase assay using a reporter construct containing repeats of this Runx2-binding site and the site-directed mutagenesis analysis. Overexpression of LMP-1 significantly increases Runx2 expression. Downregulation of Runx2 expression significantly decreases BMP-2 promoter activity and BMP-2 expression. A ChIP assay demonstrates that LMP-1 increases the interaction between Runx2 and BMP-2 promoter. A luciferase reporter assay using the OSE2 promoter containing a Runx2-binding site confirms that Runx2 transactivity can be upregulated by LMP-1. Moreover, inhibiting the activation of different pathways with specific pathway inhibitors reveals that ERK1/2 MAPK activation is essential for LMP-1-induced upregulation of Runx2 transactivity and subsequent BMP-2 expression. In conclusion, our novel findings describe a positive regulatory effect of LMP-1 on BMP-2 expression and BMP-2-mediated osteogenesis. This effect occurs through activation of ERK1/2 pathway and subsequent upregulation of Runx2 transactivity.
LIM 矿化蛋白-1(LMP-1)是骨形成的细胞内调节剂。已经证明,骨形态发生蛋白(BMPs)的上调和 BMP/Smad 信号的稳定是 LMP-1 增强成骨作用的关键机制。然而,LMP-1 如何调节 BMPs 的表达和相关的骨形成仍不清楚。在这项研究中,使用 LMP-1 诱导的成骨细胞模型来研究 LMP-1 对 BMP-2 表达和骨形成的分子作用。结果表明,LMP-1 的过表达显著增加,而内源性 LMP-1 的下调则减少 BMP-2 的表达和骨形成。BMP-2 的拮抗剂 noggin 或短发夹 RNA(shRNA)BMP-2 显著减弱了 LMP-1 的成骨作用,表明 LMP-1 的成骨作用是由 BMP-2 介导的。通过使用包含 BMP-2 启动子的报告基因构建体的荧光素酶报告基因测定,发现 LMP-1 对 BMP-2 的调节发生在转录水平。启动子缺失测定表明,-1000/-500 bp 是 LMP-1 调节的关键区域。然后在 -934/-920 bp 处定位到一个 Runx2 结合位点,并通过包含该 Runx2 结合位点重复序列的报告基因构建体和定点突变分析的荧光素酶测定进行了验证。LMP-1 的过表达显著增加了 Runx2 的表达。Runx2 表达的下调显著降低了 BMP-2 启动子活性和 BMP-2 的表达。ChIP 测定表明,LMP-1 增加了 Runx2 与 BMP-2 启动子之间的相互作用。使用包含 Runx2 结合位点的 OSE2 启动子的荧光素酶报告基因测定证实,Runx2 转录活性可以被 LMP-1 上调。此外,使用特定途径抑制剂抑制不同途径的激活,表明 ERK1/2 MAPK 激活对于 LMP-1 诱导的 Runx2 转录活性上调和随后的 BMP-2 表达是必需的。总之,我们的新发现描述了 LMP-1 对 BMP-2 表达和 BMP-2 介导的成骨作用的正向调节作用。这种作用是通过激活 ERK1/2 途径和随后上调 Runx2 转录活性来实现的。